{'fraction_non_alphanumeric': 0.041791044776119404, 'fraction_numerical': 0.022388059701492536, 'mean_word_length': 5.573529411764706, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 1, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti-inflammatory therapy: exploring exercise, serum-derived bovine immunoglobulin/protein isolates, and ruxolitinib for the cancer-associated weight loss syndrome.

DOI:10.1097/SPC.0000000000000014 In this issue of Current Opinion in Supportive and Palliative Care, seven articles focus on the cancer-associated weight loss syndrome. Taken together, these articles describe a spectrum of purported mechanisms to explain cancer-associated weight loss syndrome – including inflammation. Such mechanisms outline relevant therapeutic targets for a syndrome characterized by weight loss, worsening appetite, unremitting fatigue, increasing debility, and early death. Indeed, inflammation is postulated to drive this syndrome, and, hence, importantly, two of the contributions in this issue – that from Maddocks and coworkers and that from Klein and co-workers – converge upon inflammation as a therapeutic target [1,2]. Yet, the investigation of anti-inflammatory agents to treat cancer-associated weight loss has endured a tumultuous history perhaps reminiscent of what Goldilocks encountered in the house of the three bears (http://www.dltk-teach.com/rhymes/ goldilocks_story.htm, accessed 13 September 2013): At the table in the kitchen, there were three bowls of porridge. Goldilocks was hungry. She tasted the porridge from the first bowl.